Esketamine Alleviates Neuropathic Pain and Inflammation via miR‐153–3p/AKT3 in CCI Rats
Pain Research and Management · 2026-01 · 2026 (1)
DOI: 10.1155/prm/5536335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Research and Management, online erschienen am 17.08.2026. Verfasst von Xiumei Zhu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Guannan County First People's Hospital, Lianyungang 223500, China. Hauptthemen laut MEDLINE: MicroRNAs, Proto-Oncogene Proteins c-akt, Neuralgia, Inflammation. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The analgesic effects of esketamine have been reported. MiR‐153–3p is a central player in multiple pathologies of neural injury. The potential interplay between them remains unclear.
Objective
This study investigated whether the analgesic effects of esketamine in neuropathic pain were mechanistically linked to miR‐153–3p. Materials and Methods Neuropathic pain was induced in rats through chronic constriction injury (CCI) of the sciatic nerve, followed by esketamine administration. Pain hypersensitivity was assessed by dynamic changes in paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL). MiR‐153–3p expression was manipulated via intrathecal injection of lentiviral‐delivered miR‐153–3p mimic. RT‐qPCR was employed for analysis of miR‐153–3p expression and AKT3 mRNA levels. Proinflammatory cytokine levels were quantified by ELISA, while protein expression was detected using Western blot. The interaction between miR‐153–3p and AKT3 was verified by RIP and luciferase reporter assays.
Results
Esketamine alleviated CCI‐induced neuropathic pain by elevating PWMT and PWTL. Esketamine also reduced proinflammatory cytokine release. MiR‐153–3p was significantly reduced in CCI rats, and esketamine administration effectively reversed its decline. MiR‐153–3p upregulation suppressed pain hypersensitivity and proinflammatory cytokines. AKT3 was a target of miR‐153–3p. AKT3 knockdown abolished the effect of MiR‐153–3p inhibition on esketamine protection.
Conclusion
Esketamine mitigated neuropathic pain and reduced proinflammatory cytokine release through the miR‐153–3p/AKT3 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Guannan County First People's Hospital, Lianyungang 223500, China.
- Department of Neurology, The Third Hospital of Hebei Medical University, Shijiazhuang 050051, China, hebmu.edu.cn.
ORCID-Profile: Yawen Zhang
Zitieren
APA
Zhu, X., & Zhang, Y. (2026). Esketamine Alleviates Neuropathic Pain and Inflammation via miR‐153–3p/AKT3 in CCI Rats. Pain Research and Management, 2026(1). https://doi.org/10.1155/prm/5536335
Vancouver
Zhu X, Zhang Y. Esketamine Alleviates Neuropathic Pain and Inflammation via miR‐153–3p/AKT3 in CCI Rats. Pain Research and Management. 2026;2026(1). doi:10.1155/prm/5536335
BibTeX
@article{Zhu2026,
author = {Zhu, Xiumei and Zhang, Yawen},
title = {Esketamine Alleviates Neuropathic Pain and Inflammation via miR‐153–3p/AKT3 in CCI Rats},
journal = {Pain Research and Management},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/prm/5536335}
}
EUVIMED